Artrya Ltd (ASX: AYA) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Artrya Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$656.74 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
163.57 million
Earnings per share
-0.172
Dividend per share
N/A
Year To Date Return
-14.44%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Artrya Ltd (ASX: AYA)
Latest News
AI Stocks
Why this ASX AI share could be a top buy in June
ASX Share Market News
5 things to watch on the ASX 200 on Tuesday
AI Stocks
Which exciting ASX AI stock is a buy according to a leading broker?
Growth Shares
2 exciting ASX shares to buy with big growth potential!
Share Gainers
Why Artrya, Cleanaway, DroneShield, and Nuix shares are pushing higher today
AI Stocks
Bell Potter just initiated coverage on this ASX AI stock with a buy rating
Healthcare Shares
Two booming ASX healthcare stocks investors should be buying the dip on
Opinions
1 ASX blue-chip share and one small-cap share to buy in 2026: experts
Technology Shares
This ASX tech stock is jumping 6% on big US AI news
AI Stocks
Up 752% in one year! This roaring ASX AI stock just hit all-time highs on major revenue milestone
Share Gainers
Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today
AI Stocks
Why is this ASX AI share jumping 11% today?
1❯
Frequently Asked Questions
-
No, Artrya has not yet paid dividends to shareholders.
-
The company, founded in 2019 in Perth, listed on the ASX on 26 November 2021.
AYA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Artrya Ltd
Artrya Ltd (ASX: AYA) is an AI-driven medical technology company that assists clinicians in the diagnosis of coronary heart disease. Artrya’s Salix Coronary Anatomy is a coronary computed tomography angiography (CCTA) image analysis solution that allows physicians with AI to identify and analyse the extent and type of arterial plaque, and help identify patients at risk of a heart attack.
The Perth-based company says the technology will revolutionise the speed and accuracy of coronary artery disease diagnosis.
AYA Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | $4.03 | $0.03 | 0.75% | 1,430,168 | $4.31 | $4.38 | $4.02 |
| 30 Jul 2026 | $4.00 | $-0.77 | -16.14% | 3,001,067 | $4.67 | $4.67 | $3.88 |
| 29 Jul 2026 | $4.77 | $-0.32 | -6.29% | 974,332 | $5.09 | $5.20 | $4.68 |
| 28 Jul 2026 | $5.09 | $-0.53 | -9.43% | 677,695 | $5.58 | $5.63 | $5.08 |
| 27 Jul 2026 | $5.62 | $-0.02 | -0.35% | 465,775 | $5.81 | $5.83 | $5.40 |
| 24 Jul 2026 | $5.64 | $-0.11 | -1.91% | 542,162 | $5.70 | $5.77 | $5.48 |
| 23 Jul 2026 | $5.75 | $0.34 | 6.28% | 442,564 | $5.65 | $5.89 | $5.50 |
| 22 Jul 2026 | $5.41 | $0.11 | 2.08% | 237,346 | $5.41 | $5.63 | $5.30 |
| 21 Jul 2026 | $5.30 | $0.06 | 1.15% | 623,674 | $5.19 | $5.39 | $5.00 |
| 20 Jul 2026 | $5.24 | $-0.12 | -2.24% | 266,207 | $5.35 | $5.41 | $5.22 |
| 17 Jul 2026 | $5.36 | $-0.15 | -2.72% | 849,042 | $5.47 | $5.47 | $5.15 |
| 16 Jul 2026 | $5.51 | $-0.31 | -5.33% | 597,409 | $5.98 | $5.98 | $5.51 |
| 15 Jul 2026 | $5.82 | $0.14 | 2.46% | 470,065 | $5.65 | $5.94 | $5.55 |
| 14 Jul 2026 | $5.68 | $0.03 | 0.53% | 322,793 | $5.60 | $5.74 | $5.54 |
| 13 Jul 2026 | $5.65 | $-0.12 | -2.08% | 592,441 | $5.80 | $5.87 | $5.50 |
| 10 Jul 2026 | $5.77 | $0.07 | 1.23% | 864,072 | $5.63 | $5.86 | $5.50 |
| 09 Jul 2026 | $5.70 | $-0.02 | -0.35% | 479,856 | $5.56 | $5.77 | $5.47 |
| 08 Jul 2026 | $5.72 | $-0.26 | -4.35% | 505,979 | $5.98 | $6.02 | $5.63 |
| 07 Jul 2026 | $5.98 | $-0.20 | -3.24% | 653,954 | $6.10 | $6.19 | $5.90 |
| 06 Jul 2026 | $6.18 | $-0.09 | -1.44% | 815,689 | $6.44 | $6.49 | $6.10 |
| 03 Jul 2026 | $6.27 | $0.36 | 6.09% | 696,802 | $5.88 | $6.39 | $5.72 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 10 Jul 2026 | Bernard (Bernie) Ridgeway | Expiry | 750,000 | $4,327,500 |
Options expired.
|
| 18 Jun 2026 | Bernard (Bernie) Ridgeway | Exercise | 750,000 | $750,000 |
Exercise of options.
|
| 18 Jun 2026 | Bernard (Bernie) Ridgeway | Buy | 750,000 | $750,000 |
Exercise of options.
|
| 11 Jun 2026 | Bernard (Bernie) Ridgeway | Sell | 300,000 | $1,380,000 |
On-market trade.
|
| 14 Apr 2026 | Bernard (Bernie) Ridgeway | Exercise | 500,000 | $500,000 |
Exercise of options.
|
| 14 Apr 2026 | Bernard (Bernie) Ridgeway | Issued | 500,000 | $500,000 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Bernard (Bernie) William Ridgeway | Non-Executive ChairmanNon-Executive Director | Feb 2021 |
Mr Ridgeway brings a wealth of corporate experience to Artrya, including 38 years in private and ASX-listed companies, spending most of that time in the role of Managing Director. Bernie was Managing Director of the ASX listed top 300 company Imdex Limited (Imdex) for 20 years, retiring in July 2020.
|
| Dr Jacque Sokolov | Non-Executive Director | Aug 2022 |
Dr Sokolov has experience across all aspects of the US healthcare industry, in particular healthcare delivery, biotechnology, and regulatory clearance. He was appointed Artrya Clinical Advisory Board Chair in January 2022 and Chairman and President of Artrya USA Inc. in March 2022. He is Chairman and Chief Executive Officer of SSB Solutions, Inc., a US diversified healthcare management, development, and financial services company. He currently serves on multiple public, private and not-for-profit healthcare boards.
|
| Ms Catherine (Kate) Hill | Non-Executive Director | Feb 2023 |
Ms Hill is a non-executive director of ASX listed companies and has experience in both technology companies and the biotech and medical devices sectors. In addition, she has experience of other listing exchanges including Nasdaq (US) and AIM (UK). She previously spent 20 years as an audit partner at Deloitte, serving both ASX-listed and privately owned clients. She has worked in regulated environments, including assisting with Initial Public Offerings, capital raising, and general compliance, as well as operating in an audit environment.
|
| Dr Jeffrey LeBenger | Non-Executive Director | Feb 2026 |
Dr Benger is a healthcare executive and physician with more than two decades of leadership experience across medical groups and value-based care delivery. He served as CEO of Summit Medical Group from 1999 and as CEO of Summit Health from 2019, following the merger with CityMD. He became Executive Chairman of Summit Health in 2021, supporting execution of their long-term strategic plan. Dr Le Benger is board certified in facial plastic and reconstructive surgery, otolaryngology, and head and neck surgery.
|
| Mr Mark Edward Pitts | Company Secretary | Mar 2026 |
-
|
| Mark Edward Pitts | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 18,325,583 | 12.37% |
| HSBC Custody Nominees (Australia) Limited | 8,696,205 | 5.87% |
| Ms Erika Henriette Konstantopoulos <Iemk Family A/C> | 7,260,000 | 4.90% |
| Ubs Nominees Pty Ltd | 7,059,963 | 4.77% |
| Mr John Barrington <Bht Family A/C> | 6,950,103 | 4.69% |
| BNP Paribas Noms Pty Ltd | 5,216,414 | 3.52% |
| Richcab Pty Ltd | 4,878,115 | 3.29% |
| Netwealth Investments Limited <Wrap Services A/C> | 3,544,879 | 2.39% |
| Mutual Trust Pty Ltd | 3,163,249 | 2.14% |
| Keeble Nominees Pty Ltd <Ridgeway Self Managed Super Fund A/C> | 3,121,025 | 2.11% |
| Zanya Nominees Pty Ltd <Jls Superannuation Fund A/C> | 2,845,636 | 1.92% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 2,712,620 | 1.83% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 2,191,576 | 1.48% |
| J P Morgan Nominees Australia Pty Limited | 1,967,765 | 1.33% |
| Healthliant Ventures Llc | 1,797,760 | 1.21% |
| Mr Paul Ernest Neilsen & Mrs Julie Louise Neilsen | 1,732,361 | 1.17% |
| Lightview Asset Pty Ltd | 1,598,175 | 1.08% |
| Ian Sandover & Associates Pty Ltd Handover Super A/C> | 1,555,000 | 1.05% |
| Gaziton Pty Ltd <The Miller Super Fund A/C> | 1,500,000 | 1.01% |
| Pgta Family Pty Ltd <Pgta Family A/C> | 1,300,000 | 0.88% |
